As noted before, METTL3-m6A-EGFR-axis was responsible for acquired resistant to lenvatinib, and the particular METTL3 inhibitor STM2457 amplified tumor response to lenvatinib in HCC animal models via increasing cell apoptosis 40. The gene discussed is METTL3; the disease is neoplasm.